NCI and FDA are recruiting three medical oncologists who would divide their time between clinical and regulatory duties—half at the FDA Office of Oncology and Hematology Products, and half at the NCI Center for Cancer Research.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
